ABSTRACT
A review of the statistics of the years 2003, 2004 to August 2005 has provided data corresponding to 255 patients that were diagnosed and included in the treatment protocol of chronic hepatitis C. Epidemiologically, the 2/1 man/woman ratio, mean age of 43 years and history of transfusion (transf.) in 18.6% are to be noted. Parenteral drug addicition (PDA) in 17% and alcoholism in 14.1%, of unknown origin in 58.74% of the cases. 79.05% corresponded to genotype 1, 4.74% to genotype 4, 14.22% to genotype 3, and 2.76% to genotype 2. Genotypes 1 and 4 were included in the treatment regime with PEG-Interferon alpha-2b + Ribavirin (with doses adjusted for weight) and those of genotype 3 and 2 in the regime with Interferon alpha 2b + Ribavirin. In 95 cases of Genotype 1 (87) and 4 (8), a sustained viral response (SVR) of 61.95% was obtained, with three drop-outs. In the 20 cases of genotypes 3 (17) and 2 (3), SVR was 85%, with no drop-outs. In the 20 cases of genotypes 3 (17) and 2 (3), SVR was 85%, with no drop-outs. The adjustment of treatment to body mass involved an economic savings per case amounting to 868.94 Euro. Finally, in 16 cases of Genotype 1, before treated with Interferon in monotherapy, a sustained viral response of 31.25% was obtained with combined therapy.
Subject(s)
Antiviral Agents/therapeutic use , Hepatitis C, Chronic/drug therapy , Adult , Female , Hepacivirus/drug effects , Hepacivirus/immunology , Hepatitis C, Chronic/blood , Hepatitis C, Chronic/epidemiology , Humans , Liver Function Tests , Male , Treatment OutcomeABSTRACT
Revisando la estadística de los años 2003, 2004, hasta agosto de 2005, tenemos datos correspondientes a 255 pacientes que fueron diagnosticados e introducidos en protocolo de tratamiento de hepatitis crónica por virus C. Epidemiológicamente es de destacar la proporción de 2/1 entre hombre/mujer, edad media de 43 años y antecedentes de transfusión (Transf.) en un 18,6%. Adicción a drogas por vía parenteral (ADVP) en el 17% y etilismo del 14,1%, siendo el origen desconocido en el 58,74% de los casos. Correspondieron al genotipo 1 el 79,05% de los casos, genotipo 4 el 4,74%, genotipo 3 el 14,22% y genotipo 2 el 2,76%. Los genotipos 1 y 4 fueron introducidos en protocolo de tratamiento con PEG-interferón alfa-2b + ribavirina (con dosis ajustadas según peso) y los de genotipo 3 y 2 con interferon alfa 2b + ribavirina. En los 95 casos de genotipo 1 (87) y 4 (8), se obtuvo una respuesta viral sostenida (RVS) del 61,95%, con tres abandonos. De los 20 casos de genotipos 3 (17) y 2 (3), la RVS fue del 85%, sin ningún abandono El ajuste del tratamiento al peso supuso un ahorro económico por caso, teniendo sólo en cuenta PEG-interferón, que se cifró en 868,94 e. Por último, grupo de 16 casos del genotipo 1 había sido tratado anteriormente con interferón en monoterapia, consiguiéndose con el nuevo tratamiento una RVS en 5 casos de los primeros (31,25%)
A review of the statistics of the years 2003, 2004 to August 2005 has provided data corresponding to 255 patients that were diagnosed and included in the treatment protocol of chronic hepatitis C. Epidemiologically, the 2/1 man/woman ratio, mean age of 43 years and history of transfusion (transf.) in 18.6% are to be noted. Parenteral drug addcition (PDA) in 17% and alcoholism in 14.1%, of unknown origin in 58.74% of the cases. 79.05% corresponded to genotype 1, 4.74% to genotype 4, 14.22% to genotype 3, and 2.76% to genotype 2. Genotypes 1 and 4 were included in the treatment regime with PEG-Interferon alpha-2b + Ribavirin (with doses adjusted for weight) and those of genotype 3 and 2 in the regime with Interferon alpha 2b + Ribavirin. In 95 cases of Genotype 1 (87) and 4 (8), a sustained viral response (SVR) of 61.95% was obtained, with three drop-outs. In the 20 cases of genotypes 3 (17) and 2 (3), SVR was 85%, with no drop-outs. In the 20 cases of genotypes 3 (17) and 2 (3), SVR was 85%, with no drop-outs. The adjustment of treatment to body mass involved an economic savings per case amounting to 868.94 e. Finally, in 16 cases of Genotype 1, before treated with Interferon in monotherapy, a sustained viral response of 31.25% was obtained with combined therapy
Subject(s)
Adult , Humans , Antiviral Agents/therapeutic use , Hepatitis C, Chronic/drug therapy , Hepacivirus/chemistry , Hepacivirus/immunology , Hepatitis C, Chronic/blood , Hepatitis C, Chronic/epidemiology , Liver Function TestsABSTRACT
No disponible
Subject(s)
Humans , Ribavirin , Hepacivirus , Hepatitis C, Chronic , Treatment Outcome , Antiviral Agents , Interferons , GenotypeABSTRACT
Embolism is very frequently found in patients with infective endocarditis (IE), fundamentally in cerebral arteries. An early diagnosis and possible complications seem to be related to morbidity and mortality. Echocardiography has a considerable function in early diagnosis, and, also, when we evaluate the risk of major cerebral embolism. However there is no agreement in the second aspect: for some authors echocardiography only slightly aids, but others consider it of great value in identifying high-risk patients. We describe a patient who suffers infective endocarditis by Staphylococcus aureus with significant neurological complications in its evaluation. Vegetation was disclosed by transesophageal echocardiography (TEE), whereas transthoracic echocardiography (TTE) was unable to do so. This is why we underline the role of TEE in the diagnosis and description of vegetation features (size, mobility and implantation) which seem to be linked to the risk of cerebral complications.
Subject(s)
Echocardiography, Transesophageal , Endocarditis, Bacterial/diagnostic imaging , Intracranial Embolism and Thrombosis/diagnostic imaging , Staphylococcal Infections/diagnostic imaging , Adult , Endocarditis, Bacterial/complications , Humans , Intracranial Embolism and Thrombosis/etiology , Male , Risk Assessment , Staphylococcal Infections/complicationsABSTRACT
OBJECTIVE: Assessment of four eradicating patterns of 6 and 12 days duration with new triple therapies adapted to our environment. PATIENTS: After an endoscopic diagnosis of Duodenal or Gastric Ulcer, and the confirmation of the presence of Helicobacter pylori using a rapid urease test in antral biopsies, 274 patients were treated with one of four eradicating therapies, verifying its efficacy with the C-13 urea breath test, at least one month after the end of the treatment and 10 days after withdrawal of proton pump inhibitors. RESULTS: Maximum eradicating efficacy was achieved with Omeprazole (20 mg/12 hours), Clarithromycin (500 mg/12 hours) and Amoxycillin (1 g/12 hours), given for 12 days (96.6%), and Omeprazole (20 mg/12 hours), Tinidazole (500 mg/12 hours) and Clarithromycin (500 mg/12 hours), also given for 12 days (95.2%). The same drugs and doses, when given during six days, achieved percentages of 78.3% and 82.2% respectively. Results with Tinidazole suggest lack of resistance to this drug in the Community of Madrid.
Subject(s)
Amoxicillin/administration & dosage , Anti-Bacterial Agents/administration & dosage , Anti-Ulcer Agents/administration & dosage , Clarithromycin/administration & dosage , Helicobacter Infections/drug therapy , Helicobacter pylori , Omeprazole/administration & dosage , Penicillins/administration & dosage , Tinidazole/administration & dosage , Drug Administration Schedule , Female , Helicobacter Infections/diagnosis , Helicobacter pylori/isolation & purification , Humans , Male , Time FactorsABSTRACT
A review was made of the differences between 21 cases of Crohn's disease and 40 cases of ulcerative colitis, diagnosed in the same 10-year period. In terms of sex, age, symptoms, location, complications and evolution, the findings were similar to those obtained in England and northern Europe.
